Barbara Fontanals-Cirera
Overview
Explore the profile of Barbara Fontanals-Cirera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
635
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davalos V, Lovell C, Von Itter R, Dolgalev I, Agrawal P, Baptiste G, et al.
Nat Commun
. 2023 Apr;
14(1):1867.
PMID: 37015919
Metastatic melanoma develops once transformed melanocytic cells begin to de-differentiate into migratory and invasive melanoma cells with neural crest cell (NCC)-like and epithelial-to-mesenchymal transition (EMT)-like features. However, it is still...
2.
Song W, Agrawal P, Von Itter R, Fontanals-Cirera B, Wang M, Zhou X, et al.
Nat Commun
. 2021 Feb;
12(1):1214.
PMID: 33619278
Melanoma is the most lethal skin malignancy, driven by genetic and epigenetic alterations in the complex tumour microenvironment. While large-scale molecular profiling of melanoma has identified molecular signatures associated with...
3.
Santamaria P, Floristan A, Fontanals-Cirera B, Vazquez-Naharro A, Santos V, Morales S, et al.
Cell Death Differ
. 2017 Dec;
25(5):935-950.
PMID: 29229995
Lysyl oxidase-like 3 (LOXL3) is a member of the lysyl oxidase family comprising multifunctional enzymes with depicted roles in extracellular matrix maturation, tumorigenesis, and metastasis. In silico expression analyses followed...
4.
Fontanals-Cirera B, Hasson D, Vardabasso C, Di Micco R, Agrawal P, Chowdhury A, et al.
Mol Cell
. 2017 Nov;
68(4):731-744.e9.
PMID: 29149598
Bromodomain and extraterminal domain inhibitors (BETi) represent promising therapeutic agents for metastatic melanoma, yet their mechanism of action remains unclear. Here we interrogated the transcriptional effects of BETi and identified...
5.
Agrawal P, Fontanals-Cirera B, Sokolova E, Jacob S, Vaiana C, Argibay D, et al.
Cancer Cell
. 2017 Jun;
31(6):804-819.e7.
PMID: 28609658
Association of aberrant glycosylation with melanoma progression is based mainly on analyses of cell lines. Here we present a systems-based study of glycomic changes and corresponding enzymes associated with melanoma...
6.
Vardabasso C, Gaspar-Maia A, Hasson D, Punzeler S, Valle-Garcia D, Straub T, et al.
Mol Cell
. 2015 Jun;
59(1):75-88.
PMID: 26051178
Histone variants are emerging as key regulatory molecules in cancer. We report a unique role for the H2A.Z isoform H2A.Z.2 as a driver of malignant melanoma. H2A.Z.2 is highly expressed...
7.
Di Micco R, Fontanals-Cirera B, Low V, Ntziachristos P, Yuen S, Lovell C, et al.
Cell Rep
. 2014 Sep;
9(1):234-247.
PMID: 25263550
Transcription factors and chromatin-remodeling complexes are key determinants of embryonic stem cell (ESC) identity. Here, we demonstrate that BRD4, a member of the bromodomain and extraterminal domain (BET) family of...
8.
Segura M, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro M, Hanniford D, Zhang G, et al.
Cancer Res
. 2013 Aug;
73(20):6264-76.
PMID: 23950209
Metastatic melanoma remains a mostly incurable disease. Although newly approved targeted therapies are efficacious in a subset of patients, resistance and relapse rapidly ensue. Alternative therapeutic strategies to manipulate epigenetic...